摘要
2022年12月, 欧洲甲状腺学会(ETA)联合美国甲状腺学会(ATA)发布了甲状腺眼病(TED)诊治共识声明。以平衡治疗方式的获益与风险为出发点, 该共识对核心治疗方式的适应证做出了具体推荐, 还介绍了TED的诊疗决策、基础治疗与护理及风险因素控制等共计34个重点推荐内容。
In December 2022,the European Thyroid Association(ETA)and American Thyroid Association(ATA)jointly released a consensus statement on the diagnosis and management of thyroid eye disease(TED).Taking into account the benefits and risks,the consensus provides specific recommendations for essential therapeutic agents.It also covers 34 key recommendations on the diagnosis and treatment decision-making,basic therapy and care,and risk factor control for TED.
作者
罗耀升
李章芳
沈洁
Luo Yaosheng;Li Zhangfang;Shen Jie(Department of Endocrinology,the Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,China;Department of Endocrinology and Metabolism,the Third Affiliated Hospital of Southern Medical University,Guangzhou 510630,China;Department of Endocrinology and Metabolism,Shunde Hospital of Southern Medical University(the First People′s Hospital of Shunde),Foshan 528308,China)
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2023年第7期555-559,共5页
Chinese Journal of Endocrinology and Metabolism
关键词
甲状腺眼病
治疗共识
生物制剂
Thyroid eye disease
Treatment consensus
Biological agent
